Navigation Links
Neurocrine Biosciences Completes 'Petal Study' Treatment Phase for Endometriosis
Date:6/17/2008

rovera injection every 3 months. After completing the 6-month treatment phase, subjects continue in the blinded trial for additional DXA, safety and clinical evaluations at 6 and 12 months post treatment per Food and Drug Administration (FDA) recommendations. The collection of treatment phase data, quality control processing and statistical analyses will take place over the upcoming weeks. As announced previously, Neurocrine is on track to report this treatment phase topline data in early September 2008.

The Petal Study will contribute to the extensive data set of 10 Phase I studies, 2 Phase IIa studies and 3 Phase IIb studies that will serve as the basis for end-of-phase II discussions anticipated in 2009 with the Division of Reproductive and Urologic Drug Products at the FDA.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's GnRH program and R & D pipeline and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's GnRH program include, but are
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Neurocrine Biosciences Reports First Quarter 2008 Results
2. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
3. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
4. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
5. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
6. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
7. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
8. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
9. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
10. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
11. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... OAKS, Calif. , June 19, 2013 Amgen ... the United States , Canada ... this year,s recipients of the Amgen Award for Science Teaching ... extraordinary teachers at the kindergarten through 12th grade level who ... in science education. With a long-standing commitment to ...
(Date:6/19/2013)... Pharmacyclics, Inc. (the "Company") (Nasdaq: ... Journal of Medicine ( NEJM ) published results ... oral Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib in patients ... lymphoma (SLL). Ibrutinib was shown to be safe and ... in patients who were at high-risk due to factors ...
(Date:6/19/2013)...   NextDocs announced today that it will ... at DIA 2013 , the Drug Information Association ... studies that explore best practices for making the transition ... file (eTMF) systems. Sharon Ames , ... Krystyna Kowalczyk , executive vice president of clinical operations ...
Breaking Medicine Technology:Amgen Award For Science Teaching Excellence Honors Outstanding Teachers 2Amgen Award For Science Teaching Excellence Honors Outstanding Teachers 3Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 2Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 3Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 4Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 5Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 6NextDocs and Novella to Present on eTMF at DIA 2013 2
(Date:6/19/2013)... STRATFORD, Conn (PRWEB) June 20, 2013 A man ... same man he used to be. In his debut book titled ... a war veteran who immerses himself back home, looking for the ... When Gabriel De Los Angeles, former marine from the Vietnam War, ... to take the edge off his PTSD. Wings, a wealthy acquaintance ...
(Date:6/19/2013)... Across the globe billions of people live ... the medical advances that benefit developed western society. ... and the necessary aid to help curb the conditions ... Outlook with Ben Kingsley is partnering with some ... these people live and highlight the invaluable resources being ...
(Date:6/19/2013)... 2013 HASCO Medical, Inc. (OTCBB: ... intent to purchase privately held Auto Mobility Sales, ... wheelchair accessible vehicle sales, service and rentals in ... Inc compliments and expands HASCO's strategy of becoming ... dealers . The acquisition is subject to customary ...
(Date:6/19/2013)... 2013 Kleritec, Inc. announced the addition ... http://www.kleritec.com . In the recent expansion Kleritec ... activities packages for pre-school and day care providers. The ... to aid teachers across the United States the ability ... , Included in the art and activities packages is ...
(Date:6/19/2013)... Citi Bike has come to New York City in ... to know for sure how many patients will choose to take ... the option. In fact, he’s happy about anything that might ... it more convenient for them to visit his office at 133 ... Alternative Medicine at Back and Body Medical and an experienced ...
Breaking Medicine News(10 mins):Health News:Rafael Fragauda’s New Book Underlines Post Traumatic Stress Disorder 2Health News:HASCO Medical, Inc. to Acquire Auto Mobility Sales, Inc. 2Health News:Kleritec Announces Addition of Educational Products. 2Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 2Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 3
... Cuts Will Reduce Access to Care for Millions ... , , ARLINGTON, Va., Sept. 16 ... recommendations for healthcare reform in his long-awaited "Chairman,s mark" version of ... home medical equipment, ranging from power wheelchairs to anti-fraud measures. The ...
... strong disapproval of contraception might be a factor , ... are higher in states with greater levels of religious ... new U.S. study suggests. , In the study, researchers ... on teen birth rates with data from the Pew ...
... , PANAMA CITY, Fla., Sept. 16 ... staff washing their hands when moving from patient to patient can ... Commission , handwashing failures contribute to healthcare-associated infections ... hospitals $4 billion to $29 billion annually to combat. At ...
... , MINNEAPOLIS, Sept. 16 Today ClearWay ... and thanked outgoing members for their service to the organization. David ... as the new Board Chair. The full roster of Board Officers ... David Fisher, Board Chair - An attorney ...
... , , , SAN DIEGO, ... Diego based medical device company, today announced that its application for ... technology has been approved by the Food and Drug Administration. The ... , , Jim Hitchin, SpectraScience,s, CEO said, ...
... InVitria to ... in Animal Cells (PEACe) in Jackson Hole, WY, Sept. 19-23. , ... Fort Collins, CO (PRWEB) September 16, 2009 -- InVitria ... supplements at the 9th Annual PEACe conference to be held in Jackson Hole, WY, Sept. ...
Cached Medicine News:Health News:Senate Finance Committee Cuts Home Medical Equipment in Reform Package 2Health News:Bay Medical Fights Healthcare-Associated Infections by Improving Hand Hygiene 300% 2Health News:Bay Medical Fights Healthcare-Associated Infections by Improving Hand Hygiene 300% 3Health News:Bay Medical Fights Healthcare-Associated Infections by Improving Hand Hygiene 300% 4Health News:ClearWay Minnesota(SM) Board Approves New Officers 2Health News:SpectraScience Receives FDA Approval for Enhancements to WavSTAT(R) Optical Biopsy System 2Health News:InVitria Cell Culture Product Line to Headline PEACe 2
... 1 Block MBS Start up kit. ... software and choice of 1 MultiBlock ... to 30 blocks. User friendly software. ... Adjustable height heated lid. Outstanding ...
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
96 well format, Gradient features tests 12 PCR annealing temperatures in 1 run...
... The latest addition to our ... cyclers is the personal-sized GeneAmp ... instrument for both basic PCR ... represents the culmination of several ...
Medicine Products: